Skip to main content
Alan Ho, MD, Oncology, New York, NY

AlanLohHoMD

Oncology New York, NY

Instructor, Medicine, Weill Cornell Medical College

Overview of Dr. Ho

Dr. Alan Ho is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, NYC Health + Hospitals / Bellevue, and New York-Presbyterian Hospital. He received his medical degree from Washington University in St. Louis School of Medicine and has been in practice 14 years. Dr. Ho accepts several types of health insurance, listed below. He is one of 64 doctors at NYC Health + Hospitals / Bellevue and one of 375 doctors at New York-Presbyterian Hospital who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2005 - 2009
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2003 - 2006
  • Washington University in St. Louis School of Medicine
    Washington University in St. Louis School of MedicineClass of 2003

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2004 - 2026
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers  
    Steven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
  • Multi-Dimensional Genomic Analysis of Myoepithelial Carcinoma Identifies Prevalent Oncogenic Gene Fusions  
    Ian Ganly, Alan L Ho, Ronald Ghossein, Nadeem Riaz, Cristina R Antonescu, Nora Katabi, Nature

Lectures

  • Alliance A091404: A phase II study of enzalutamide (NSC# 766085) for patients with androgen receptor-positive salivary cancers. 
    2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

  • HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
    HOOKIPA Pharma Doses First Patients with Eseba-Vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck CancerOctober 30th, 2024
  • Long-Term Follow-up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options for Recurrent or Metastatic HNSCC
    Long-Term Follow-up Confirms Pembrolizumab and Pembrolizumab-Chemotherapy as Effective First-Line Treatment Options for Recurrent or Metastatic HNSCCOctober 14th, 2022
  • Enzalutamide in Advanced Androgen Receptor-Positive Salivary Gland Cancer
    Enzalutamide in Advanced Androgen Receptor-Positive Salivary Gland CancerAugust 4th, 2022
  • Join now to see all

Professional Memberships

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Multiplan PHCS PPO
    Multiplan PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    QualCare HMO
    QualCare PPO
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment